Impairment of adipocyte lipolysis via adipocyte-specific ATGL deletion improves systemic glucose homeostasis and protects from hepatic steatosis by reducing fatty acid delivery to non-adipose tissues, and subsequently, lipotoxicity6–8. The gene discussed is PNPLA2; the disease is fatty liver disease.